Can a new potential treatment combining an SGLT-2 and a GLP-1 RA mitigate cardiometabolic risk?
Read More »Ertugliflozin Proved Effective in Patients with Type 2 Diabetes and ASCVD
A VERTIS CV sub study showed significant improvements in glycemic control after adding ertugliflozin to insulin-based regimens.
Read More »ADA 81st Symposium: Evidence-Based Guidelines For Diabetes and Chronic Kidney Disease
Diabetes is the leading cause of chronic kidney disease due to microvascular damage to the renal blood vessels.
Read More »ADA 2021: Lowering of Blood Pressure and Pulse Rate by Switching from DPP-4 Inhibitor to Luseogliflozin in Patients with T2D and Hypertension
Researchers investigate the changes in ambulatory blood pressure using the antidiabetic drug in patients with type 2 diabetes and hypertension.
Read More »Greater Weight Loss Found With SGLT-2 Inhibitors Than GLP-1 RAs in Patients with T2D
Contrary to previous studies, new research finds SGLT-2i more effective for weight loss than GLP-1 RAs as add-on therapy to Metformin.
Read More »Know the Side Effects of the Drugs You Prescribe
Male, 72 years of age, type 2, insulin-requiring diabetes, also taking SGLT-2. Annual physical. No urinary complaints during the visit. Received annual lab work end of the workday, glucose elevated much higher than the reports. WBC elevated, 1200, no urine culture, but U/A did show cloudy....
Read More »ADA 2021: Dapagliflozin Use in Patients with COVID-19
Dapagliflozin has shown clinical effectiveness in some of the same metabolic processes that are affected by COVID-19, but can it help treat patients who have contracted the virus?
Read More »ADA 2021: Summary for Classification, Prevention, and Treatment of Heart Failure in Patients with Diabetes
American Diabetes Association mini-symposium presented by Biykem Bozkurt, MD, Ph.D., FHFSA, FACC, FAHA, FESC.
Read More »ADA 2021: Economic Benefits of Initiating Empagliflozin vs. GLP-1 Receptor Agonist
The study evaluates the healthcare cost associated with two principal therapies for patients with type 2 diabetes.
Read More »Cardiovascular and Kidney Outcomes when Discontinuing SGLT-2 Inhibitor
After starting SGLT-2i, is the discontinuation of therapy necessary if there is an immediate decline in estimated Glomerular Filtration Rate (eGFR) in patients?
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.